Newsletter

Stay up to date on all things heart attack. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Impact of Daylight on Patients With Acute Myocardial Infarction

Jun 11, 2019

Overview

 

Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is believed to have an effect. The circadian system in humans is based on the rotation of the earth with day and night. When humans wake up, light shines in their eyes and signals the day has started. For the human body it means that certain proteins (named clock, period etc) are produced. The protein that determines the length of a day (awake and sleep period) is called Period 2 (Per2). Recent data has shown that the Per2 protein in hearts from mice is produced after daylight exposure (the daylight of the daylight beach was used to measure  — approx. 10 000 LUX). This more Per2 was able to protect the heart from being damaged by no overflow of blood going to the heart. This protection was based on a more efficient use of carbohydrates. They conclude the heart needs less oxygen and current data shows that human Per2 is also induced by light exposure and can be detected in human plasma samples.

 

In this clinical trial Per2 transcript and protein levels will be analyzed in patients that just experienced a heart attack with and without intense daylight therapy utilizing blood samples.

 

Study Information

 

This is a non-randomized, interventional, parallel assignment with the purpose of treatment for heart attack patients. There is an estimated 30 participants. The study began July 2015 and is expected to end by July 2019.

 

Inclusion Criteria

 

  • All sexes, ages 18 to 90 years old
  • Patients with an acute myocardial infarction (history of heart attack)
  • Healthy volunteers
  • Must speak and understand English

 

Exclusion Criteria

 

  • Patients with an acute myocardial infarction (heart attack) but are too sick from other illnesses, e.g. severe symptoms, chest pain, generally unstable, etc.

 

Location

 

You may participate in this study at the University of Colorado in Denver, Colorado, United States, 80220-3706. IF you have any questions or concerns please contact Colleen M Bartman, PhD at 330-607-6539 or at colleen.bartman@ucdenver.edu.

 

Sponsors/Collaborators

 

This study is sponsored by the University of Colorado, Denver with Tobias Eckel, MD, PhD as the Principal Investigator.

Clinical Trials

View All

Testing a Community Intervention to Increase Aspirin Use

Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men,

MRI of Myocardial Infarction

Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year.

CLEAR SYNERGY Neutrophil Substudy

CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and ant

Evaluating Vitamin D Normalization on Cardiovascular-Related Events

This study evaluates whether achieving 25-hydroxyvitamin D, or  25[OH] Vit D (what vitamin D is converted into whe

The Impact of Early Follow-up on Readmission Rates in AMI Patients

This study aims to conduct the first randomized, prospective trial to better clear up the association between early

Testosterone Replacement and Exercise Capacity in Hypogonadal Men

This study examines the effect of testosterone replacement on the ability to exercise for men with functional compe

Women’s Heart Attack Research Program

This clinical trial examines a higher than normal number of platelets, plate

Send this to a friend